Professor David MacMillan of
Princeton University delivered the Scynexis Lecture at the University of North
Carolina in Chapel Hill last week. He discussed a recently disclosed technology
that may be suitable for late-stage diversification of a range structurally
complex natural products, including medicinally relevant steroids and
triterpenoids. The new reaction uses both photoredox and
organic catalysis to accomplish allylic C-H arylation of an unfunctionalized
olefinic precursor. The C-C bond forming process accommodates a range of alkene
reactants including the unprotected steroidal 5-pregnen-3b-ol-20-one substrate depicted above. Due to its dual catalysis mechanism involving single-electron
transfer (SET), the arene coupling partner must be highly electron-deficient
and the majority of the transformations reported in the 2015 Princeton manuscript employ
either a dicyanobenzene or 4-cyanopyridine.
Mechanistically, the reaction involves
two synergistic catalysis cycles (as outlined in the scheme above). Initial
photoactivation of a commercially available iridium(III) catalyst with visible
light generates an excited state complex that engages the electron-deficient
arene in a single-electron reduction. The SET reduction step affords an
intermediary ‘persistent’ radical anion, along with an iridium(IV) oxidant species.
Next, the resultant oxidant triggers an organocatalytic cycle, wherein a thiol
catalyst is converted to a thiyl radical with concomitant regeneration of
Ir(III). An allylic hydrogen atom is then abstracted from the olefinic reactant
by the newly formed thiyl radical. Finally, radical-radical coupling between
the persistent arene radical and the more reactive allylic radical, followed by
elimination of cyanide, furnishes the arylation product containing a new C-C
bond. While somewhat narrow in scope with regard to the aromatic coupling
partner, the new allylic arylation reaction is operationally simple to conduct,
requires only commercially available catalysts and proceeds under mild
conditions. MacMillan's conceptually novel chemistry should open up new opportunities for late-stage
diversification of complex organic molecules, an R & D strategy that is of
great interest to the pharmaceutical industry.